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Despite efforts to reduce malaria morbidity and mortality, drug-resistant parasites continue to evade control 
strategies. Recently, emphasis has shifted away from control and toward regional elimination and global 
eradication of malaria. Such a campaign requires tools to monitor genetic changes in the parasite that could 
compromise the effectiveness of antimalarial drugs and undermine eradication programs. These tools must be 
fast, sensitive, unambiguous, and cost-effective to offer real-time reports of parasite drug susceptibility status 
across the globe. We have developed and validated a set of genotyping assays using high-resolution melting 
(HRM) analysis to detect molecular biomarkers associated with drug resistance across six genes in Plasmodium 
falciparum. We improved on existing technical approaches by developing refinements and extensions of HRM, 
including the use of blocked probes (LunaProbes) and the mutant allele amplification bias (MAAB) technique. 
To validate the sensitivity and accuracy of our assays, we compared our findings to sequencing results in both 
culture-adapted lines and clinical isolates from Senegal. We demonstrate that our assays (i) identify both known 
and novel polymorphisms, (ii) detect multiple genotypes indicative of mixed infections, and (iii) distinguish 
between variants when multiple copies of a locus are present. These rapid and inexpensive assays can track drug 
resistance and detect emerging mutations in targeted genetic loci in P. falciparum. They pro- vide tools for 
monitoring molecular changes associated with changes in drug response across populations and for determining 
whether parasites present after drug treatment are the result of recrudescence or reinfection in clinical settings. 
T he Malaria Eradication Research Agenda (malERA) initiative recently reported (19) that development of 
new tools for surveillance and detection of drug-resistant parasites is imperative for any successful eradication 
effort. Rapidly expanding genetic data sets for malaria can be leveraged to identify molecular bio- markers 
related to important parasite characteristics, which could be key for surveillance. 
 
Arguably, the most well studied and clinically important sets of molecular biomarkers are genetic loci associated 
with resistance to antimalarial compounds. Resistance to aminoquinolines, such as chloroquine, and antifolates, 
such as pyrimethamine and sulfadoxine, is widespread, and molecular markers associated with these resistant 
phenotypes have been identified. Specifically, researchers have identified genetic changes in the pfcrt locus for 
chloroquine resistance (12), the dhfr locus for pyrimethamine and proguanil resistance (23, 24), and the dhps 
locus for sulfadoxine resistance (5). Other candidate molecular biomarkers for drug resistance are pfmdr1 (13, 
27), associated with resistance to amodiaquine and other aminoquinolines; cytb, associated with atovaquone 
resistance (15, 17); and PfATPase6, implicated in artemisinin resistance (6, 16, 25). New discovery efforts, 
including genome-wide association studies, are beginning to identify additional candidate loci related to drug 
resistance (20, 26, 31); these loci will need to be validated in independent parasite populations. 
 
It is critical that assays identify additional candidate loci related to drug resistance for known and newly 
discovered molecular biomarkers to be developed in order to easily and reliably examine samples from infected 
patients identified through positive blood smears. Because the parasite population changes readily and radically 
in response to selective pressure from drugs and other intervention methods, eradication policies must be equally 
responsive and adaptable. The data from these assays must allow real-time observation of parasite population 
changes to inform timely protocol changes and further global eradication efforts to reduce or even eliminate child 
deaths from malaria. 
 
While a number of assays have been developed for drug resistance loci, they rely on technologies that are not 
suited to real-time detection and discovery of single-nucleotide polymorphisms (SNPs) associated with reduced 
drug sensitivity. Many of these technologies, like pyrosequencing and real-time PCR (29, 32), require extensive training and the use of expensive reagents on instruments in regional clinic settings, which means that samples 
collected in the field can wait months or years for analysis. Other technologies, such as restriction fragment 
length polymorphism (RFLP) and msp1, msp2, and glurp marker typing, are economical to implement, but 
interpretation of results can be complicated and dependent on the user’s skill level or lead to results that cannot 
be directly compared between studies (21). These limitations reduce the utility of existing methodologies for 
global surveillance campaigns and emphasize the need for assays that are portable, cost-effective, and 
uncomplicated. 
 
In this report, we describe a novel modified high-resolution melting (HRM) method for real-time genotyping of 
malaria, using parasites derived from culture-adapted isolates. We validate these highly sensitive and robust 
assays by examining known drug resistance loci found in patient blood samples from Senegal. We also report the 
discovery of new genetic variants for several genetic loci known to be involved in modulating drug resistance. 
 
MATERIALS AND METHODS 
DNA extraction and quantification. We utilized culture-adapted parasites and clinical isolates from a number of sources. 
Culture-adapted Plasmodium falciparum parasites obtained from the Malaria Research and Reference Reagent Repository 
(http://MR4.org) included 3D7 (MRA- 151, deposited by D. Walliker), 7G8 (MRA-152, deposited by D. Wal- liker), Dd2 
(MRA-156, deposited by T. E. Wellems), D10 (MRA-201, deposited by Y. Yu), FCR3 (MRA-731, deposited by W. Trager), 
V1/S (MRA-176, deposited by D. E. Kyle), W2 (MRA-157, deposited by D. E. Kyle), W2mef (MRA-615, deposited by A. F. 
Cowman), K1 (MRA-159, deposited by D. E. Kyle), and TM90C6B (MRA-205, deposited by D. E. Kyle). Culture-adapted P. 
falciparum parasites obtained from the Walter Reed Army Institute of Research (WRAIR) included W2, W2mef, and WMCI. 
We obtained an additional 27 P. falciparum clinical samples un- der human subject informed consent conditions from patients 
being evaluated at the SLAP clinic in Thies, Senegal, during 2007. The research and ethics study was approved by the Harvard 
School of Public Health Institutional Review Board (IRB) and the Ministry of Health in Senegal. Written informed consent 
was obtained in the subjects’ own language. 
 
We isolated genomic DNA from culture-adapted parasites using the QIAmp DNA Blood Mini Kit (Qiagen catalog number 
51106), Qiagen G-100 (catalog number 13343), and Promega Maxwell 16 Blood DNA Purification Kit (Promega catalog 
number AS1010). We preserved DNA from patient blood samples by using Whatman FTA filter paper (Whatman catalog 
number WB120205), and isolated DNA using the QIAmp DNA Blood Mini Kit (Qiagen catalog number 51106), the 
GenSolve Blood Spot Kit (GenVault catalog number GVR-50), or the Promega Maxwell DNA IQ Casework Sample Kit 
(Promega catalog number AS1210). We quantified DNA using a Nanodrop 1000 (Thermo Scientific) or a real-time 
quantitative PCR assay with a labeled probe for hypothetical P. falciparum gene PF07_0076, as previously described (8). We 
used 0.01 ng of P. falciparum patient sample template material per reaction. 
 
Primer and probe design. We imported genomic sequence of the laboratory strain 3D7 from PlasmoDB version 6.3 
(http://www.plasmodb .org) into Idaho Technology, Inc. Primer Design Software (version 1.0.R.84). We selected primer and 
probe sets ranking in the top 10 out of 1,000 potential set designs for SNPs located in six genes across the P. falciparum 
genome: pfcrt (C72, M74, N75, K76, H97, A220, N326, and I356), pfdhfr (N51, C59, I164, and S108), pfdhps (S436, G437, 
K540, A581, and A613), cytB (Y268), pfATPase 6 (L263, E431, A623, and S769), and pfmdr1 (N86, Y184, R371, S1034, 
N1042, and D1246). We designed the probes to contain the SNP of interest. Where several SNPs existed in close proximity on 
the genome, we designed the probe to cover as many of the SNPs as possible. We determined likely melting peak separation 
between mutant and wild-type alleles on these probes using Hybridization Probe Melting Temperature Software v1.5 and 
uMelt (Idaho Technology, Inc.) (10). These applications allowed us to determine peak separation, but the actual melting peak 
temperatures depended on the actual amplification reaction conditions. We discarded designs that did not show at least 1.5°C 
difference between melting peaks and redesigned many to increase that difference. We ordered probes with a 3’ block (a C3 
spacer phosphoramidite attached to a standard 3’ CpG) to prevent extension during PCR amplification. Table 1 lists primer 
and probe sequences. 
 
Amplification conditions and equipment. We optimized the assay amplification conditions on a 96-well microtiter plate 
system using a gradient thermocycler (Bio-Rad iCycler), followed by HRM analysis on a LightScanner-96 (Idaho Technology, 
Inc., Salt Lake City, UT). We per- formed all PCR amplification reactions using 2.5ul LightScanner master mix with LCGreen 
Plus double-stranded DNA (dsDNA) dye (Idaho Technology, Inc.) and primers and probes at various concentrations for assay 
optimization. We used cultured P. falciparum strains with previously reported genotype profiles for wild-type and mutant 
SNPs to test the performance of the assays in detecting both alleles. Where we did not have samples with all possible mutant 
SNPs for an assay, we generated con- structs containing those mutated positions and used them as controls for the assays 
(miniGenes; Integrated DNA Technologies). We verified all products by sequencing by Genewiz (Genewiz, Inc., Cambridge, 
MA) on an ABI 3730xl DNA analyzer and with BigDye Terminator v3.1 chemistry using the company’s sample submission 
requests. 
 
Once optimized for 96-well plate systems, we transferred the technology directly to a LightScanner-384 to increase assay 
economy. 
 
We performed PCR using a gradient thermal cycler to determine optimal annealing temperatures for asymmetric PCR conditions, with one primer in 5:1 or 7:1 excess and the probe at 80 to 100% of the concentration of the excess primer (data 
not shown). Asymmetric PCR is essential to probe-based amplification, producing excess single-stranded material that binds 
to the blocked probe, which increases the signal needed for probe melting analysis. For assays crtH97, cytBY268, and 
mdrS1034, the optimal asymmetric ratio of forward to reverse primers was 5:1; for the remaining assays, the asymmetry was 
1:5. The final primer concentration was 0.5 uM excess primer and 0.1 uM limiting primer. The final reaction concentration of 
the 3’-blocked probes was 0.4 uM. 
 
The best amplification and melting conditions depended on the instrument used for HRM. On the LightScanner-96 or -384, 55 
cycles of a three-step program performed best. For assays dhfrS108, mdrD1246, ATPase6S769, crtI356, and crtA220, the 
reaction mixtures were denatured for 2 min at 95°C and denatured, annealed, and extended at 94°C, 63°C, and 74°C for 30 s 
each, with a final step at 95°C for 30 s. All remaining assays had an annealing temperature of 66°C instead. 
 
With glass capillaries used in the LightScanner-32 (LS32; Idaho Technology, Inc.), which transfer heat much more efficiently 
than the plate- based LightScanner-96 and -384, the amplification cycle was 95°C denaturation for 2 min, followed by 55 
cycles of 94°C for 5 s and 66°C for 30 s, and then a premelt cycle of 5 s each at 95°C and 37°C. Following PCR, the amplified 
products were analyzed using HRM on the LightScanner instruments. Products were heated from 40 to 90°C and the change in 
fluorescence recorded incrementally. Standard software included with the instruments were used for unlabeled probe analysis 
to visualize melting peaks based on these changes in fluorescence. 
 
Once we selected an optimal annealing temperature for pure allelic samples, we implemented a novel amplification protocol to 
preferentially increase the amplification of mutant alleles in mixed samples. The mutant allele amplification bias (MAAB) 
technique is an experimental approach used in samples suspected of containing very small fractions of mutant alleles in a 
single sample. MAAB uses decreased annealing temperature during PCR amplification to increase the melting signal from the 
mutant allele in mixtures. Amplification bias of the mutant allele is accomplished by using a probe design that is perfectly 
matched to the normal, or wild- type, allele. 
 
We developed MAAB protocols on a LightScanner-32 to take advantage of the high temperature transition rate capability, 
which is critical for optimal performance of the MAAB technique. This instrument utilizes capillary tubes in a 5- to 10-￿l 
reaction volume and offers real-time PCR and automated high-resolution melting analysis capability. The glass capillary 
reaction vessels accommodate the requisite rapid temperature transitions required for MAAB. Optimal annealing temperatures 
under MAAB were reduced to 52 to 56°C. 
   TABLE 1 High-resolution melting assay primer and probe sequences Assay SNP 
    
FIG 1 Representative melting peaks of HRM assays. (A) Example of a single-SNP probe assay; Pfcrt H97 shown. The probe is 
designed to be a perfect match to the wild type (3D7). Any mutations in this probe region lower the melting peak. Shown here is 
TM90C6B with the mutation H97Q that results from a nucleotide base change from A to T. This class IV SNP is the most challenging 
for HRM to distinguish. (B) Example of a single-SNP probe assay with multiple alleles. Pfmdr 86 shows wild-type N86 in 3D7 (gray), 
mutant N86Y in strains K1 and FCR3 (red), and a recently reported mutation in field isolates, N86F in Dd2 (blue). Note that different 
sources of Dd2 have varying numbers of copies of pfmdr1. In this instance, Dd2 has copies with different SNP mutations that have 
been sequenced to verify the presence of both alleles. Both N86Y and N86F derive from an A¡T nucleotide change. Additionally, the 
SNPs tested are adjacent to one another in the genome and can be clearly differentiated by the assay. (C) Representative SNP 
haplotype probe assay. Shown is the assay developed for pfcrt residues 72, 74, 75, and 76. The probe is designed as a perfect match to 
the 3D7 allele at each locus (codons 72, 74, 75, and 76); thus, sample 3D7(blue) displays the highest melting peak (Tm ) possible with 
this probe. This peak corresponds to a genotype at these four loci of C,M,N,K. Sample 7G8 (red) is mismatched under the probe at 
codons 72 (TT mismatch) and 76 (CT mismatch) for a genotype of S,M,N,T. Samples Dd2, V1/S, and FCR3 (gray) are all the same 
genotype and are mismatched to the probe at codons 75 (GT and AA mismatch; 1st and 3rd bases of codon 75) and 76 (CT mismatch), 
making the genotype C,I,E,T. If a sample were mismatched with the probe at only a single base site, the melting peak would be 
somewhere between the red and blue peaks. If a sample were mismatched at all 4 sites, the melting peak would be even lower than the 
gray peak. 
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We designed a set of 23 HRM assays using the 3’-blocked LunaProbe technology to genotype SNPs across six 
genes previously associated with reduced drug sensitivity. These assays failed traditional TaqMan primer/probe 
design requirements, but HRM design was successful. The LunaProbe technology has been shown to increase 
assay sensitivity: the addition of 3’-blocked probes covering short (less than 50-bp) regions within the primer 
amplicon results in enhanced peak melting-temperature (Tm) separation between alleles, especially class IV 
SNPS (A->T or T->A) that are a challenge to differentiate with traditional HRM methodologies (Fig. 1A and B). 
LunaProbes also allow separation of SNPs located very close or adjacent to each other in the genome (Fig. 1B 
and C). This improved design resulted in better peak separation than previously reported with HRM (1). We 
confirmed the genotypes determined by HRM analysis through direct sequencing of the amplicons, finding 100% 
correspondence of the observed genotypes to the reported sequences. 
 
Our genotyping assays proved to be robust and specific. They were able to detect and differentiate alleles with 
low concentrations of template material even in the presence of excess contaminating genomic material. Using 
cultured isolates without excess human material, as would be found in filter-extracted patient samples, the limit 
of detection was 10
-5 ng, similar to that found by other groups (Fig. 2A) (1, 14) and also similar to other PCR-
based methodologies and comfortably within the yield from extraction of patient samples collected on filter 
paper in the field. The assays remained specific for their target regions in the presence of an excess of human 
genomic material that we introduced in order to mimic the ratios of human and parasite DNAs obtained from 
patient samples; however, the absolute limit of detection with contaminating human DNA was reduced to 
approximately 10 pg (Fig. 2B). 
    
 
FIG 2 Limit of detection and performance with human genomic material. (A) Limit of detection of assays. A representative assay 
(pfdhps 436/437) shows the limit of detection. The melting peaks are still distinguishable, with 10￿5 ng of Plasmodium template as the 
lowest curves. Shown are the normalized derivative melting peaks of both the probe and full amplicon (the higher-temperature melting 
peaks outside the vertical bars of the probe amplicon). (B) Limit of detection of assays with software normalization. The same assay 
shown in panel A after software normalization of the probe melting peaks (Idaho Technology, Inc., standard software suite analysis of 
unlabeled probes) still shows strong peaks for the mutant and wild-type alleles. (C) Performance with an excess of human material. 
Shown are mock samples of culture-adapted parasite genomic material with an excess of human material added. The Pfcrt K72-76 
assay is shown. The limit of detection is 10 pg of parasite template combined with 1 ng of human DNA. 
   
R
e
l
a
t
i
v
e
 
S
i
g
n
a
l
 
(
%
)
Temperature  C
Normalized Melting Peaks
52 54 56 58 60 62 64 66
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
A
Figure 2
Genotype or Haplotype
C;M;N;K
C;I;E;T
S;M;N;T
B
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
52 54 56 58 60 62 64 66
R
e
l
a
t
i
v
e
 
S
i
g
n
a
l
 
(
%
)
Temperature  C
-0.05
-0.05
C;M;N;K
S;M;N;T
C;I;E;TThe genotyping assays are also sensitive and were made more so by our technology modifications. We were able 
to detect alleles comprising 2% to 5% of the total sample; by introducing the novel amplification method MAAB 
on a LightScanner-32 instrument using glass capillary tubes, we were able to increase the sensitivity to detect 
mutant alleles present at less than 1% of the mixture (Fig. 3B). There is some vertical spread between the mixture 
peaks; however, the inflection for each mixture does not change com- pared to the negative or peak curve seen 
with the unmixed samples. This inflection difference is consistent across repeated trials and is reliable as long as 
unmixed controls are present. 
 
Remarkably, we could discriminate individual alleles even in more complex mixtures containing three or more 
alleles using our modified HRM approach (Fig. 3A). These results demonstrate that the assays are sensitive and 
specific and are able to identify alleles present at less than 1% of a mixture when multiple alleles exist in a 
sample. Comparable amplification technologies, such as TaqMan, fail to consistently detect mutant alleles at less 
than 10% of the sample mixture (8). Without the refinements to HRM using blocked probes, the typical 
sensitivity for detection is still an improvement at 2 to 5%. 
 
Additional methods, such as nested-PCR amplification and RFLP analysis, rely on more subjective and 
complicated interpretation of gel bands. Here, we show that HRM analysis results in clearly separated and 
unambiguous melting peaks to determine sample genotypes. 
 
To assess the accuracy and reliability of these assays, we applied them to genotype 44 independent, culture-
adapted parasites from a number of different geographical regions and verified our results by sequencing 
(Genewiz, Inc., South Plainfield, NJ) (Table 2). From our assays, we found that 40% of the samples had the mu- 
tant genotype for pfcrt K76 and 18% and 40% displayed variants at dhps residues 436 and 437, respectively. For 
dhfr, 65% were mutants at residues 51 and 59, and 70% were mutants at residue 108. While many other SNPs 
associated with drug resistance were primarily wild-type genotypes, there were variant polymorphisms in this 
international collection for each of the following loci: pfcrt 220 (40%) and 356 (12.5%), pfmdr1 86 (32.5%) and 
184 (70%), and PfATPase6 (40%). All mutations detected by genotyping assays were confirmed by sequencing 
(Genewiz, Inc., South Plainfield, NJ), and our assays showed 100% correlation with the sequencing results, as 
well as those reported on PlasmoDB version 6.3 (http: //www.plasmodb.org). The genotyping assays are also 
sensitive and were made more so by technology improvements. These data 
 
    
FIG 3 Assay performance with mixtures of genomes and MAAB. (A) Mixture of three genomes showing clear differentiation 
between fractions: 3D7-7G8- Dd2. The pfcrtK72-76 assay is shown. (B) MAAB. Shown in the pfcrt K72-76 assay, MAAB in the 
LightScanner-32 increases the likelihood of detecting low- frequency allele fractions in a mixed population. Different proportions of 
mu- tant DNA were mixed with wild-type DNA as follows: 100% wild-type DNA (3D7), a 50/50 mixture of mutant DNA (7G8) with 
wild-type DNA (3D7), a 25/75 mixture of mutant DNA (7G8) and wild-type DNA (3D7), and so on down to less than 1% mutant 
DNA mixed with wild-type DNA in 1 ng total template concentration. 
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We next tested the correspondence of our genotyping assays with drug phenotypes among the culture-adapted 
parasites (2). We evaluated the K76 locus of pfcrt associated with chloroquine resistance and the N51, C59, and 
S108 loci of dhfr associated with pyrimethamine resistance. We observed 100% correspondence between the 
pfcrt K76T mutation and chloroquine resistance among culture-adapted parasites. We also observed 100% 
correspondence between the N51I allele (100%) and the C59R allele (100%) in dhfr for pyrimethamine 
resistance. For the S108N allele, four of the parasites deviated from direct correspondence with pyrimethamine 
resistance. Three of the parasites that had the S108N allele tested sensitive to pyrimethamine. These parasites 
were wild type for the N51 and C59 alleles and had pyrimethamine resistance levels near the cutoff (2,000 nM) 
for resistance (3). One parasite that had the S108 allele tested resistant to pyrimethamine. This parasite, however, 
was mutant for the N51I and C59R alleles and also had a level of pyrimethamine resistance that was just over the 
resistance cutoff level of 2,000 nM. Thus, we observed almost complete correspondence between the genotyped 
alleles and the expected drug responses for chloroquine and pyrimethamine among the culture-adapted parasites 
in this analysis, confirming that these molecular markers are useful for interpreting drug responses in P. 
falciparum parasites. 
 
We then demonstrated the usefulness of our HRM assays on materials derived from blood collected on filter 
paper from patients seeking treatment for malaria at the Thies, Senegal, clinic. Table 2 shows the prevalences of 
mutations in the following loci: pfcrt 76 (15%), dhps 436 (26%) and 437 (48%), and dhfr 51 and 59 (85%) and 
108 (93%). Other SNPs with variant alleles include pfcrt 220 (26%) and 356 (22%), pfmdr1 86 (7%), pfmdr1 
184 (70%), and PfATPase6 623 and 431 (7%). Based upon comparison to data from previous years, there has 
been a decrease in the prevalence of mutations associated with chloroquine resistance and an increase in 
mutations associated with pyrimethamine resistance. The decrease in chloroquine resistance but increase in 
pyrimethamine resistance is consistent with the use of these drugs for ma- laria treatment in Senegal. While 
chloroquine use has largely been discontinued, use of pyrimethamine has continued (initially in a combination 
treatment with sulfadoxine and amodiaquine) and remains the mainstay treatment for intermittent preventative 
treatment for pregnant women (IPTp) in Senegal to date (30). 
 
While traditional probe-based technology approaches fail to amplify if novel variants appear within the amplicon 
region, our assays allowed us to detect both known and novel haplotypes and mutations in genetic loci associated 
with drug resistance. Techniques such as TaqMan require prior knowledge of all sequence variants for successful 
genotyping in order to design labeled probes for every polymorphism. We have demonstrated that our method, 
on the other hand, is far more robust and can identify novel variants. First, we detected previously unreported 
haplotypes in Senegal for pfdhps 436/437 in three of the culture-adapted parasite lines, including the 436A/437A 
haplotype for two parasites (P05.02 and Th105.07), as well as the 436Y/437G haplotype for another parasite 
(Th28.04) (Fig. 4A). Second, we detected a new mutation in the cytB locus from a single patient sample (Fig. 
4B). This novel mutation, confirmed by sequencing (Genewiz, Inc., South Plainfield, NJ), is the M270I variant, 
located near the amino acid associated with atovaquone resistance in the cytB gene at Y268 (17). Because this 
novel allele was detected in direct patient material, we were unable to test for any biological effects of the 
mutation on drug sensitivity. Because the probe-based analysis also allows study of the larger amplicon, we were 
able to dis- cover SNPs 22 bp upstream of the probe region but still within the amplicon targeted by the ATPase6 
431 assay in D10 (MRA-201) (data not shown). The additional utility of focusing on genomic regions known to 
be under selection is the increased likelihood that additional mutations associated with reduced drug sensitivity 
will be found in the regions targeted by the assay primers that may confer drug resistance. While samples with 
variant melting peaks must be sequenced to characterize the emerging mutation, HRM technologies offer the 
unique ability to quickly and economically scan samples for emerging variants. 
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FIG 4 Detection of emerging and new mutations. (A) New SNP haplotype detected in Senegal patient samples. The pfdhps 
436A/437A and 436Y/437G haplotypes have not previously been reported in Senegal, though they have been reported in other 
regions. (B) Novel mutation in cytB. The plot of melting peaks shows the expected wild-type Y268 and mutant S268 peaks as controls 
in gray and red, respectively. The new mutation, M270I, confirmed by sequencing, is shown in blue. 
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BIn addition, the assays differentiated between copies of a genetic locus. The pfmdr1 locus is known to be present 
in multiple copies in some drug-resistant parasites, particularly those resistant to mefloquine (13, 28). As part of 
this analysis, we observed different genotypes for the pfmdr1 locus in the Dd2 parasite and confirmed the 
presence of the newly reported pfmdr1 N86F mutation in Dd2 (4, 9). This demonstrates the ability of these 
assays to detect mutations among loci subject to copy number variation, which has been implicated in some 
drug-resistant parasites (11, 18, 22). Copy number variation has also been identified as a source of reduced 
sensitivity to antimalarial drugs. Instruments with real-time capacity (Idaho Technology LightScanner-32 and 
Qiagen Rotorgene-Q) offer additional utility of these assays for direct detection of these variations. 
Finally, we demonstrated that our assays distinguish between single and mixed alleles, in both culture-adapted 
and clinical samples. Multiple melting peaks appearing in single-genome infections determined by molecular 
barcode or other methods (8) suggest that there are variant copies of the genetic locus in the parasite genome 
(Fig. 1). 
 
DISCUSSION 
High-resolution melting technology offers a new tool for first-line surveillance of known and emerging markers 
associated with reduced sensitivity to drug treatments. While it does not replace standard protocols, such as 
sequencing, to characterize the specific genetic changes, the method is economical and easy to implement in a 
large number of global regions to scan the parasite population for changes that could signal the emergence or 
importation of known mutations. As new mutations are detected through the technology, they can be 
characterized by sequencing, and new HRM assays can be rapidly developed in an iterative process of population 
tracking. 
 
Several other groups have presented HRM assays applied to P. falciparum (1, 7, 14); however, the techniques 
presented here show clear advances over the previous works. We have implemented a probe-based technique that 
improves the sensitivity of these assays over the whole-amplicon methodology presented in the work of 
Andriantsoanirina et al. and similar to the technology presented by both Gan and Loh and Cruz et al. 
Compared to the previous publications, we have developed and validated an extended set of assays for SNPs 
related to reduced drug sensitivity and have made notable advances in the ability to detect mutant alleles present 
in small amounts within a sample, an improvement on both studies, which noted a 10% limit of detection of 
mutant alleles while we have detected mutant alleles at less than 1%. While MAAB is most effective in 
instruments that use glass capillaries for their improved heat transfer properties, the method could be especially 
useful for surveillance of emerging resistance where the primary causative SNP is known. The ability to detect 
these mutations at very low levels can inform control efforts. MAAB could be applied following larger-scale 
plate-based screens where the results may indicate the presence of a minor population of mutants. MAAB could 
confirm these observations. 
 
Further, we applied these assays to determine the SNP genotypes of 27 patient samples with both single and 
mixed infections and were able to detect the emergence of haplotypes new to Senegal. Like Gan and Loh, we 
identified new mutations within the probe region but also found evidence of new mutations outside the probe but 
within the larger amplicon. 
 
With this technology, results are robust, consistent, and repeatable; however, several caveats exist. Care must be 
taken in preparing the reaction mixtures. Salt concentrations have a strong effect on the melting temperature of 
the complexes, so it is advised that all samples be in the same buffer for the most consistent results. Not all 
samples have to be at the same concentration, but the reactions are most reliable with low concentrations of tem- 
plate. They become less so with an excess of template (more than10 ng/ul), and the melting peaks may shift even 
if all samples are in the same buffer if any of them are at a very high template concentration relative to the other 
samples. While most groups report femtogram levels of detection within culture-adapted strains without human 
genomic material, the sensitivity of the assays decreases when this human contaminant is present in the sample. 
Still, we observed universally robust amplifications and unambiguous genotypes from 0.005 to 0.01 ng of P. 
falciparum template from patient-derived samples that had not been depleted of white blood cells. 
HRM is a promising technology for field-based studies; however, the success of the results also depends on the 
quality of the analysis software that is included with the HRM analysis instruments. Currently, no standalone 
application exists for melting analysis. We have had the best success with the suites offered by Idaho 
Technology, Inc., as a combination of sensitive analysis and ease of peak calling without extensive and 
complicated user training. User training will be further reduced as researchers publish additional validated assays 
that require no further optimization. Our initial panel of 23 assays is a strong start toward this goal. 
Because our HRM assays are sensitive, work on mixed infections, and are easily deployed to study field samples, 
they have the capacity to track both current and emerging infections. Our genotyping assays can be used to monitor the frequencies of known drug resistance alleles or parasite types within a population. Furthermore, they 
can elucidate changes in these frequencies as interventions or other factors that impact transmission dynamics in 
a given population. For example, as molecular markers of emerging drug resistance are discovered, these 
markers can be monitored across a population to determine the likelihood that current drug therapies would 
remain effective or to inform policies to contain the spread of emerging drug resistance and detect the 
importation of drug-resistant parasites. Because these assays do not require fluorescence-based probes, the 
reagent cost per sample is much lower than for alternative technologies, and storage and preparation conditions 
are much less stringent. In our hands, HRM costs approximately 2/3 of what TaqMan-based SNP genotyping 
costs and have less than 1/10 the cost for sequencing all of these regions. In addition, the assays are reliable for 
samples collected on filter paper, a low-cost method for sample preservation, transportation, and storage. The fast 
readout of the melting analysis is clear and unambiguous, allowing easy interpretation of results and less 
specialized researcher training. 
 
With increased efforts to establish global networks of research centers based on-site across the globe, such as the 
International Centers of Excellence for Malaria Research (ICEMR) and the collaborative efforts of the Gates 
Foundation, the initial capital expenditures for equipment capable of high-resolution melting analysis can be 
distributed across sites. In addition, many of these instruments are multipurpose and are able to offer real-time 
analysis in addition to HRM. 
 
Our rapid and field-deployable genotyping tools have great promise for surveillance and clinical diagnosis as we 
transition from malaria control to malaria elimination. For malaria elimination to be successful, tools that can 
provide quick and reliable information about the changing dynamics of parasites in the natural setting are key. 
Such information includes monitoring drug- resistant loci in parasites or determining whether a parasite persists 
after drug treatment. Our genotyping assays work on small amounts of patient-derived material and can 
disentangle information from mixed parasite infections. These assays can be used to track parasites and 
determine the sources of emerging infections. 
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